After raising $125 million for its commercialization efforts earlier this year, portable dialysis machine manufacturer Outset Medical is now going public with a $241.7 million Nasdaq IPO.

Cala Health presented new real-world data showing that its watch-like wearable electric stimulation device could be effective in improving hand control in people with essential tremor.

MicroRNA biotech miRagen is taking a good, hard look at its pipeline, and it’s putting Chief Operating Officer Lee Rauch in charge of the review—and the company.

Fitbit’s latest smartwatch has now secured medical device clearances in the U.S. and Europe, unlocking the full use of its ECG app to help identify cases of the irregular heart rhythm known as atrial fibrillation.

AstraZeneca’s Tagrisso is effective in treating EGFR-mutated non-small cell lung cancer (NSCLC), but patients often become resistant to the drug over time. Researchers at the University of Texas MD Anderson Cancer Center and BridgeBio’s Navire Pharma developed a drug to block key resistance mechanisms, and now they’re headed to clinical trials backed by positive results in mice.

Sirtex Medical, maker of a radioactive microsphere implant for treating liver tumors, has made a strategic investment in the developer of a prostate cancer therapy featuring laser-charged gold particles, Nanospectra Biosciences.

A smart contact lens with an actively working artificial iris could become a solution for people with chronic migraines, dry eyes and oversensitivity to light, according to researchers in Belgium.

This month, Tmunity Therapeutics expects to finish enrolling an early clinical trial testing an engineered CAR-T immune cell therapy for metastatic prostate cancer. The trial’s start is notable, and not just because it’s been challenging to recruit patients for cancer trials during the COVID-19 pandemic. The experimental CAR-T is among the first cell therapies to target a solid tumor—an enemy that was once considered too difficult to tackle with that type of treatment.

Frequency Therapeutics’ hearing loss treatment showed early signs of efficacy last year, with some patients showing improvements after a few months. Now, as the biotech plugs away at a phase 2a study, it’s reporting new data showing the drug’s effects lasting as far out as 21 months.

After raising $1.1 billion earlier this year to back a new slate of biotechs, Flagship Pioneering has raised the curtain on an artificial intelligence company focused on discovering and designing a wide range of new drugs.